All Stories

  1. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis

    Article • Alimentary Pharmacology & Therapeutics, June 2017, Wiley

    Marek horynski, Elena Mikhailova